Argireline vs Palmitoyl Dipeptide-6
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
ArgirelineSkin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6- Summary
- Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Half-Life
- N/A — topical application; effect duration linked to formulation contact time
- Not applicable (topical)
- Admin Route
- Topical
- Topical
- Research
- —
- —
- Typical Dose
- 5–10% concentration
- 0.005–0.05% in formulation
- Frequency
- Twice daily
- Once or twice daily
- Key Benefits
- Reduces depth of dynamic expression wrinkles 17–27%
- Non-invasive topical Botox alternative
- Smooths forehead, eye area, nasolabial fold lines
- Widely studied — published clinical efficacy data
- Synergistic with SNAP-8 for enhanced effect
- Reduces fine lines around eyes (crow's feet)
- Improves skin smoothness and texture
- Well tolerated across all skin types
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- Side Effects
- Generally very well tolerated
- At >10%: temporary eyelid/brow ptosis (drooping)
- Rare: mild redness in sensitive skin
- No systemic absorption at cosmetic doses
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Stacks With
- —
- —